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Key Points
• A high frequency of diverse
activating mutations in
costimulatory/TCR-related
signaling genes occurs in
AITL and other TFH-derived
PTCL.
• Deregulated TCR activation
may play a role in the
pathogenesis of TFH-derived
PTCL, paving the way for
developing novel targeted
therapies.
Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from fol-
licular T-helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas
(PTCLs) with poorly understood pathogenesis and unfavorable treatment results. We
investigated a series of 85patientswithAITL (n572) or other TFH-derivedPTCL (n513)
by targeted deep sequencing of a gene panel enriched in T-cell receptor (TCR) signaling
elements. RHOA mutations were identified in 51 of 85 cases (60%) consisting of the
highly recurrent dominant negative G17V variant in most cases and a novel K18N in 3
cases, the latter showing activating properties in in vitro assays. Moreover, half of the
patients carried virtually mutually exclusive mutations in other TCR-related genes, most
frequently in PLCG1 (14.1%), CD28 (9.4%, exclusively in AITL), PI3K elements (7%), CTNNB1
(6%), andGTF2I (6%). Using in vitro assays in transfected cells, we demonstrated that 9 of 10
PLCG1 and 3 of 3 CARD11 variants induced MALT1 protease activity and increased
transcription from NFAT or NF-kB response element reporters, respectively. Collectively, the
vast majority of variants in TCR-related genes could be classified as gain-of-function.
Accordingly, the samples with mutations in TCR-related genes other than RHOA had
transcriptomic profiles enriched in signatures reflecting higher T-cell activation. Although no
correlationwithpresentingclinical featuresnorsignificant impactonsurvivalwasobserved, thepresenceofTCR-relatedmutationscorrelated
withearlydiseaseprogression.Thus, targetingofTCR-relatedeventsmayholdpromise for the treatmentofTFH-derived lymphomas. (Blood.
2016;128(11):1490-1502)
Introduction
Angioimmunoblastic T-cell lymphoma (AITL), one of the most
common peripheral T-cell lymphomas (PTCLs),1,2 comprises CD41
neoplastic T cells with a T-follicular helper (TFH) immunophenotype,
and an important reactive microenvironment.3 In addition, a subset of
PTCL not otherwise speciﬁed (PTCL-NOS) exhibiting a TFH-like
immunophenotype and overlapping characteristics with AITL are
believed to be part of the same disease spectrum.4,5 The prognosis of
AITL remains poor, with a 5-year overall survival of ;30%.1,6
Although autologous stem cell transplantation may improve the
response to conventional ﬁrst-line therapy, early disease progression
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makes it frequently impossible.7 Thus, pinpointing new druggable
targets for developing speciﬁc therapies in TFH-derived lymphomas
remains critical.
Recurrent mutations in the epigenetic regulators TET2, IDH2, and
DNMT3A have been detected in AITL and TFH-like PTCLs8,9 but
are not likely sufﬁcient to drive lymphomagenesis.10,11 A highly
recurrent dominant-negative G17Vmutation in the RHOAGTPase
was recently discovered in as much as 70% of AITL and TFH-like
PTCLs.12-14 RHOA is activated downstream of T-cell receptor
(TCR) engagement in mature T cells and is linked to cytoskeleton
reorganization after T-cell activation.12,13 Although their exact role
in human T-cell transformation remains uncertain, RHOA muta-
tions tend to co-occur with TET2 mutations, suggesting that they
represent a second event in multistep AITL lymphomagenesis.15
Finally, AITL also bears a variety of other less recurrent genetic
alterations.12,13,16
In B-cell lymphomas, constitutive B-cell receptor (BCR) signaling
via somatic mutation-induced or antigen-mediated activation of key
BCR components leads to neoplastic B-cell survival and expansion.17
Several lines of evidence suggest that TCR activation might be
similarly relevant to PTCL pathogenesis. For example, NPM1-ALK
chimeric proteins induce an intracellular cascade of events substituting
to TCR signaling in anaplastic large cell lymphoma.18 The ITK-SYK
fusion present in rare PTCLs likewise drives lymphomagenesis by
triggering antigen-independent activation of TCR signaling pathways
in mice.19 Mutations or gene fusions in costimulatory/TCR signaling
genes as CD28, FYN, PLCG1, or CARD11 have also been reported
in several PTCLs.12,20-25 However, alterations in the TCR signaling
pathway have not yet been extensively studied in TFH-related
lymphomas. Here, we focused on investigating mutations in the
costimulatory/TCR signaling cascade in a series of AITL and TFH-
like PTCLs using a targeted deep-sequencing approach. Besides
frequent RHOA mutations, we demonstrated recurrent activating
and virtually mutually exclusive mutations in costimulatory/TCR
pathway components in 49% of the cases. Notably, we found several
mutations in PLCG1 and CARD11 that we characterized as function-
ally activating in vitro. Integrated analysiswith gene expression proﬁles
indicated that TCR-mutated samples were enriched for molecu-
lar signatures, reﬂecting higher T-cell activation and proliferation.
Clinically, TCR-mutated patients receiving anthracyclin-based
chemotherapy showed an increased early progression risk compared
with patients without such mutations. These results indicate the
potential of using drugs that reduce TCR signaling for treating these
lymphomas.
Methods
Patients and tumor samples
Discovery cohort. Eleven paired tumoral and normal samples from10 clinically
annotatedAITLpatientswere subject towhole-genomesequencing (WGS,n58)
orwhole-exomesequencing (WES,n53) (supplementalTable1, availableon the
BloodWeb site).
Extended cohort. Targeted deep sequencing (TDS) was performed on
DNA extracted from frozen tissue biopsies of an extended cohort of 85 previously
untreatedpatients (72AITL,13TFH-likePTCL-NOS). In3patients, paired samples
were analyzed. These cases and associated clinical annotations (supplemental
Table 2) were collected in the framework of the Tenomic LYSA consortium.
Diagnoses were conﬁrmed by expert hematopathologists. Criteria used to deﬁne
TFH-like PTCL-NOS were previously reported.8 A subset of these patients was
analyzed forTET2, IDH2, andDNMT3Amutations inprevious studies.8,9The study
was approved by the local ethics committee (CPP Ile de France IX 08-009).
WGS, WES, and TDS
Libraries were constructed for WGS following a standard protocol.26
100-bp paired-end reads were generated using an Illumina HiSequation
2000 Sequencer (version 3 chemistry). Reads were mapped to the NCBI
Build 36.1 reference genome using the Burrows-Wheeler Aligner alignment
tool version 0.5.7, algorithm aln. Polymerase chain reaction duplicates were
eliminated using Picard version 1.38. Indels and single-nucleotide variants
(SNVs) were called using Strelka version 1.0.14, removing false-positive calls
internally.Variantswere independently identiﬁed for each tumor-germline pair,
using the germline as reference. GRCh37 coordinates of the ﬁltered indels and
SNVs were obtained using LiftOverVCF. Variants were annotated with VEP,
and their read counts were obtained using in-house scripts. Copy number
variations (CNVs) were identiﬁed using HMMcopy. Commonly deleted or
ampliﬁed regions from WGS were visually identiﬁed using the Integrative
Genome Viewer Software (IGV, https://www.broadinstitute.org/igv/). Deleted
loci and genes having SNVs and/or CNVs in at least 2 patients are listed in
supplemental Tables 3 and 4.
TDS of 69 genes (supplemental Table 5) was performed on the extended
cohort. Systematic sequencing errors were removed by adding 2 randomly
selected blood samples from 4 healthy volunteers to each run. Libraries were
prepared using theTrue-SeqCustomAmplicon kit (Illumina) and sequenced on
aMiSeqmachine (Illumina, 10003meandepth,mean coverage94%).Variants
were called using MiSeq reporter using default settings and were visually
inspected on IGV. All synonymous variants and known SNPs with an allelic
frequency .0.1% in public databases (dbSNP131, 1000 Genomes Project,
5000 Exomes project) were ﬁltered out. We excluded variants found in normal
samples, in ambiguously mapped regions from captured pseudogenes, and
in regions of low complexity. Candidate variants were independently
validated in a second round of TDS: we selectively ampliﬁed the amplicons
covering the positions of candidate mutations (IonAmpliseq kit, Life Technol-
ogies) and sequenced them on an Ion PGM System (Life Technologies; 13053
mean depth, mean coverage 91.64%). Variants were called using default settings
of the IonReporter software and reviewed with IGV. The ﬁnal variants list
(supplemental Table 6) was generated applying the following ﬁltering criteria:
(a) variants called by both platforms; (b) variants with minor allele frequency
(MAF) ,0.4; and (c) variants already described as somatic in the COSMIC
database. Filter (b) was introduced to take into account the low tumor content and
theunavailabilityofmatchednormal samples.The thresholdwasdeﬁnedbasedon
the MAF range of well-characterized AITL mutations, such as in RHOA and
CD28.12-14,25Variantswere annotated usingGeneTalk (http://www.gene-talk.de/).
Cloning and functional validation
A detailed description is provided in the supplemental Material. Brieﬂy, we
performed site-directedmutagenesis ofRHOA,PLCG1, andCARD11mutations
on cloned cDNAs into pcMV6-MycFlag (RHOA, PLCG1) (Origene, C-terminal
tag) and pcDNA3-HA (CARD11) (N-terminal tag)27 vectors. RHOA variants
were functionally assessed in vitro with rhotekin pull-down assays12-14 and SRE
(Serum Responsive Element) (Promega, Madison, WI) luciferase reporter assay
using HEK293T cells.
PLCG1 and CARD11 variants were functionally tested by ﬂuorescence
resonance energy transfer (FRET)-based determination of their ability to induce
MALT1 protease activity in HEK293T cells28 and in luciferase-based assays
using a NFAT reporter in HEK293T cells (forPLCG1) or a NF-kB reporter in
Jurkat cells deﬁcient in CARD1129 (kindly provided by Dr. Xin Lin) (for
CARD11) .
Western blot analysis
The following primary antibodies were used in western blotting: anti-HA
(Covalab Biotechnology), anti-Myc (clone 4A6, Millipore), anti-CARD11
(clone 1D12, Cell Signaling), and anti-MALT128 and anti-Actin (ab3280,
Abcam). Secondary antibodies were purchased from Jackson Laboratories.
Gene expression and enrichment analysis
Gene expression proﬁles generated by hybridization on Affymetrix U133 Plus
2.0 were available for the extended cohort.3 Rotation testing using mean ranks
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(ROMER, R package limma) was used to determine the gene set signature
enrichments in TCR_Mut compared with TCR_WT patients. A total of 304
signatures, including 23 of 50 hallmark signatures and 9 signatures from the
curated and immunogenic signature collection of the Molecular Signatures
Database (MSigDB, http://software.broadinstitute.org/gsea/msigdb), all
signatures of interest in lymphoid biology (Staudt, lymphochip.nih.gov/
signaturedb/), and 2 manually annotated sequences linked to TCR signaling,
were tested.
Clinical correlations and survival analysis
Frequency differences of categorical variables were analyzed using the
Fisher exact test, whereas differences in continuous variables were tested
with theWilcoxon rank-sum test. Overall survival (OS) was deﬁned as time
from diagnosis to death or last follow-up, whereas progression-free survival
(PFS) was deﬁned as time from treatment initiation to death or progres-

























































Figure 1. Mutational landscape of nodal TFH-derived lymphomas. The results of targeted deep sequencing of 69 genes in 72 AITL (light gray) and 13 TFH-like
PTCL (dark gray) are presented. Ten cases (8 AITL and 2 TFH-like PTCL) with no mutations detected are not represented. TET2, DNMT3A, and IDH2 mutations
available for a subset of the cases reported in previous studies8,9 are also shown. Case-mutation pairs for which data are not available are indicated by a 0. Mutated



























































Figure 2. Mutations of TCR signaling–related
genes in nodal lymphomas of TFH origin. The
intracellular pathways after TCR ligation and costimulatory
activation were reconstructed using the Ingenuity pathway
analysis (IPA) tools, the KEGG database, and other re-
ferences. Four main pathways are individualized, from left
to right: (1) PI3K pathway after CD28/TCR-dependent
FYN phosphorylation and ultimately resulting in CTNNB1
translocation into the nucleus; (2) NF-kB/NFAT pathway
proximally initiated by ITK-dependent PLCG1 activation
and resulting in NFAT1, NF-kB, and IRF4 activation;
(3) AP-1/MAPK pathway that comprises ITK-dependent
GTF2I activation, MALT1-induced JNKs activation, and
PLCG1-GRB2/SOS–induced MAPK components ac-
tivation; and (4) GTPase-dependent pathway, including
RHOA, responsible for cytoskeleton remodeling upon
costimulatory/TCR activation. The main positive inter-
actions are indicated by solid green arrows, whereas
inhibitory effects are indicated in red. The TCR signaling
elements are depicted in yellow or red if the coding genes
were mutated in ,5% or $5% cases, respectively. The
most frequently mutated genes (PLCG1, CD28, PI3K
components, CTNNB1, and GTF2I) were part of cos-
timulatory, NF-kB/NFAT, PI3K, and AP-1/MAPK intracel-
lular signaling pathways. Proteins corresponding to WT
genes are indicated in blue, and genes that were not
sequenced are in gray. ERK1, ERK2, JNK1, JNK2, and
PDK1 are protein names for MAPK1, MAPK3, MAPK8,
MAPK9, and PDPK1 genes, respectively.
1492 VALLOIS et al BLOOD, 15 SEPTEMBER 2016 x VOLUME 128, NUMBER 11
For personal use only. on January 31, 2017. by Yves Beguin www.bloodjournal.orgFrom 
Kaplan-Meier method, and hazard ratio differences were computedwith the
log-rank test.
Results
Whole-exome/genome sequencing reveals alterations in T-cell
signaling genes in AITL
Eleven tumor samples from 10 AITL patients were subject toWGS
orWES and comparedwith germline DNA (supplemental Figure 1;
supplemental Table 1). On average, 91% of the genome had.103
coverage, with 68% having .303. A mean of 27 SNVs per patient
(range 11-50)was observed in coding regions, except in a sample from
a relapsing patient with a chromothripsis pattern of structural variation
(supplemental Figure 2) and 225 SNVs. In one patient refractory to
ﬁrst-line therapy, WGS performed on tumor biopsies at diagnosis and
after 5 cycles of chemotherapy revealed a similar proﬁle of alterations,
with identical TET2 and ANKRD62 SNVs in both samples. CNV
analysis revealed multiple loci deleted in a number of patients, with 8
minimal common regions (supplementalTable3),mostly in3 patients.
A total of 39 genes had SNVs and/or CNVs in at least 2 patients
(supplemental Table 4).Apart fromRHOAG17VandTET2mutations, 9
of 39 (23%) altered genes were related to TCR (n5 7), Toll-like receptor
(n5 1), or Wnt (n5 1) signaling. Other mutations were found in genes
involved in the cell cycle (n5 5), autophagy (n5 2), or other pathways
(n 5 6). Six additional genes relevant to TCR or JAK/STAT signaling
(CTNNB1, VAV1, MTOR, CREBBP, PIK3C2G, JAK1) were altered in
one patient each. Collectively, T-cell signaling alterations were found in 7
of 10 patients.
Frequent mutations of RHOA and other TCR-related genes are
confirmed in an extended cohort of TFH-derived lymphomas
We designed a panel of 69 genes for TDS, partly based on ﬁndings in
the discovery cohort (supplemental Table 5; supplemental Figure 1)
for application on our extended cohort (supplemental Table 2). After
orthogonal cross-validation and conservative ﬁltering (supplemental
Table 6; supplemental Figure 3), we validated 70 variants in 29 genes
(Figure 1), including missenses (61), frameshifts (5), nonframeshift
deletions (2), and stop-gain mutations (2). Mutations were detected in
70 of 85 samples (82%,meanmutations per sample5 1.8).RHOA and
other TCR signaling–related genes accounted for 19 of 29 (65.5%)
mutated genes (Figures 1 and 2).
RHOA mutations include a novel activating K18N variant
RHOA was the most frequently mutated gene among those analyzed
(51/85; 60% of patients), with a similar prevalence in AITL and
TFH-like PTCL. Consistent with previous reports,12,13 the G17V
variant was found in most of the cases. We also identiﬁed a novel
K18N mutation (variant frequency [VF] [5.5%; 7.4%; 10%]) in 3
AITL patients (Figure 3A; Table 1).30-44 Both mutations occur in the





































































































Figure 3. RHOA mutations in AITL and TFH-like
PTCL. (A) Overview of the RHOA protein structure,
showing G17V (42 AITL, 6 TFH-like PTCL) and the novel
K18N (3 AITL) variants that target the highly conserved
GTP/GDP binding site of RHOA. (B) Protein blot analysis
of GTP-bound RHOA-Myc in rhotekin pull-down assay
from HEK293T cells expressing indicated RHOA con-
structs. IP, immunoprecipitation. Representative of 6
independent experiments. (C) SRE (serum-responsive
element) luciferase reporter assay monitoring the activity
of RHOA K18N mutant, compared with WT, G14V, or
G17V mutants, previously characterized as activating and
dominant-negative, respectively. Cells were stimulated
(light gray) or not (dark gray) with fetal bovine serum for
6 hours. Data are represented as mean 6 standard error
of the mean (SEM) from 4 independent experiments.
Significant differences in activation activity were deter-
mined using 2-way analysis of variance (ANOVA) with
repeated measurement (**P# .01; ***P# .001 compared
with WT). Representative western blot from a luciferase
assay experiment. Ectopic myc-tagged RHOA expression
is revealed by anti-Myc. Anti-Actin blotting serves as
loading control.
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G14V (constitutively active45), G17V (dominant-negative), K18N,
and wild-type (WT) RHOA in a pull-down assay using Rhotekin-
RBD (r binding domain) beads (Figure 3B). AlthoughRHOAG17V
already characterized as dominant-negative12-14 did not bind RBD
beads, even in the presence of fetal bovine serum, comparedwithWT,
RHOA K18N showed a marked increase of RBD beads binding
similarly to RHOA G14V (Figure 3B). Moreover, unlike RHOA
G17V that did not activate and even repressed transcription from the
SRE under serum activation, RHOA K18N markedly enhanced its
transcription (Figure 3C).
Mutations in other TCR signaling–related genes are variably
recurrent and diverse
Apart from RHOA, mutations in genes involved in TCR costimulation
or signaling were detected in 42 of 85 patients (49%) (Figures 1 and 2;
Table 1).
CD28 and TCR-proximal signaling genes. Three different
CD28 mutations—T195P, D124V, and D124E—all described
previously13,25,30were identiﬁed in 4, 2, and2AITLpatients, respectively
(8/85, 9.4%) (Figure 4A). All TFH-like PTCL were CD28-WT. T195P
andD124Vmutationsareknown toenhanceTCR/CD28-inducedNF-kB
activity in vitro.25,30 Three patients (2 AITL, 1 TFH-like PTCL; 3.5%)
harbored mutations in FYN, a TCR- and CD28-proximal kinase
component (Figure 4B). Mutations in the SH2 domain (S186L) and the
absence of phosphorylated tyrosine 531 (T524fs or Q527X mutations)
probably confer enhanced kinase activity by disrupting their inhibitory
interaction.12The2aminoacid substitutions in the tyrosinekinasedomain
of LCK observed in one AITL patient is expected to enhance its kinase
activity.46 We did not ﬁnd mutations in ICOS, ZAP70, LAT, or ITK.
NF-kB/NFAT pathway. Ten different missense mutations span-
ning the coding region ofPLCG1 (VF [2.1%; 38%])were identiﬁed in 12
of 85 patients (8 AITL, 4 TFH-like PTCL; 14.1%) (Figure 5A). Apart
from previously reported variants in adult T-cell leukemia/lymphoma
(ATLL) or in other PTCL,20-24we identiﬁed 2 novel variants (E730Kand
G869E). We generated all mutant constructs and tested their activity
against WT PLCG1 in a FRET-based reporter assay of MALT1
protease activity27,28 (Figure 5B) and in a NFAT luciferase reporter assay
(Figure 5C). Both experiments conﬁrmed that the S345F and S520F
variantswere activating.21All 6variants in thePI-PLC,SH2,SH3, andC2
domains were also activating, increasing the FRET signal by 1.7- to
threefold and the luciferase expression by four- to ﬁvefold. Of the 2 PH1
domain variants, R48W had no effect in both assays, whereas E47K
increasedNFATreporter activityby2.1-foldandFRETsignalby1.5-fold.
Point mutations in CARD11, which encodes a scaffolding protein
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Figure 4. Mapping of variants in TCR signaling genes mutated in at least 3 patients. (A) CD28: the D124V/E variants involve the extracellular part of the receptor,
whereas T195P lies in the intracellular, C-terminal, domain between the 2 domains, allowing interaction with PIK3R1 (YVKM sequence) or GRB2/VAV (PRRP sequence)
proteins. (B) FYN: the five mutations indicated occurred in three patients; 1 patient harbored 2 mutations (a); 2 mutations in adjacent positions in the SH3 domain (b)
were observed on the same allele in another patient. (C-E) PI3K subunits: when appropriate, cellular stimuli are present, the nSH2 and cSH2 domains of PIK3R1 bind
phosphorylated tyrosines (YXXM motif) in activated receptors (CD28) and adapter proteins, thereby activating the PIK3CA (p110a) catalytic subunit without releasing the
PIK3R1 (p85a) interaction with p110a through their iSH2 and ABD domains, respectively. The K141R missense affects the r-GAP domain, whereas iSH2 and the second
SH2 domains of PIK3R1 bore 2 missenses each (Q475P, T576A and G680S, V704M, respectively). The A259V mutation, described as somatic in COSMIC, affects a
linker region of PIK3R5. Finally, the L1001P point mutation affects the PIK3CA kinase domain. (F) PDK1: one inframe INDEL, one frameshift INDEL, and 3 missense
affect PDK1 protein. (G) CTNNB1: 3 previously described activating missenses affect the GSK3b inhibitory domain (exon 3), whereas the K335T activating mutation
affects the armadillo repeats region. (H) KRAS: 3 missense mutations alter 2 N-terminal nucleotide binding regions. (I) GTF2I: 5 missense mutations affect the GTF2I
transcription factor, among which two are found in different GTF2I-like domains. (J) VAV1: 2 frameshift deletions and 2 missenses affect VAV1, three being localized in
the C-terminal SH3 domain of the protein. In all figure panels, previously described activating mutations are in green boldface, and mutations previously described but not
functionally tested are underlined. PDK1 is the protein name of PDPK1 gene.
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activation,28 were found in 2 AITL and 1 TFH-like PTCL (3.5%). The
F176C variant affects the coiled-coil domain of the protein, commonly
mutated in diffuse large B-cell lymphoma (DLBCL).27 The S547T
and F902C variants map to linker regions with undeﬁned structure
(Figure 5D). In a FRET-based assay,28 F176C and S547T enhanced
MALT1 proteolytic activity by two- and fourfold, respectively,
whereas the F902C mutant, previously reported in ATLL patients,20
had no detectable effect (Figure 5E).When transfected into Jurkat cells
deﬁcient for CARD11,29 we found that, compared withWT CARD11,
all 3 variants induced enhanced NF-kB reporter activity in response to
phorbol myristate acetate/ionomycin stimulation (Figure 5F).
PI3K pathway. Six patients (3 AITL, 3 TFH-like PTCL; 7%)
showed mutations in PI3K genes encoding the regulatory subunits
PIK3R1 (n5 5), PIK3R5 (n5 1), or the catalytic subunit PIK3CA
(n 5 1) (Figure 4C-E). These mutations likely enhance the
catalytic subunit activity or increase PIK3R1 binding to CD28.31
Five AITL patients (5.9%) had mutations in PDPK1 (PDK1), a
master serine/threonine kinase with multiple targets including
AKT. Three missense mutations were found on or near its kinase
domain, suggesting an activating effect47 (Figure 4F). Four
different CTNNB1 mutations, known to occur in a variety of
carcinomas and Wilms’ tumors, were identiﬁed in 5 patients
(4 AITL, 1 TFH-like PTCL; 5.9%) (Figure 4G). All have been
previously characterized as activating or stabilizing variants that
induce persistent signaling and increased proliferation, and have
been linked to both poor treatment response and frequent tumor
relapse in various tumors.32,33
AP-1/MAPK pathway. Eleven patients (8 AITL, 3 TFH-like
PTCL; 13%)hadmutually exclusive activatingmutations in theMAPK
pathway, which regulate the activity of the AP-1 transcription factor
family. Activating KRAS34 and STAT326,35 mutations were detected in
3 and 2 patients, respectively (Figure 4H). We also found 5 missense
mutations inGTF2I (TFII-I)48 (Figure 4I),which are likely activating as
those reported in thymic epithelial tumors.49
GTPases pathway. Apart from highly recurrent RHOA muta-
tions, 4 patients (3 AITL, 1 TFH-like PTCL; 4.7%) harbored
previously undescribed frameshift deletions or missense mutations
in VAV1, a guanosine exchange factor for RAC1, CDC42, and
RHOA (Figure 4J). Two missense mutations were on the second
SH3 domain, where a D797 residue mutation was previously
shown to activate VAV1-mediated transformation via cell-cell
contact deregulation.50
Analysis of sequential biopsies. Analysis of paired samples in
4 refractory or relapsed patients (supplemental Table 8) showed that the
mutations identiﬁed at diagnosis were also present in the second biopsy,
with overall very similar VF. Within the limit of the panel of genes
examined, 2 patients presented one additional mutation at relapse
(CTNNB1 and VAV1), at somewhat lower VF than those present at
diagnosis. Although this analysis is limited to a few pairs of samples, it
indicates that themutational heterogeneity that characterizesmanyAITL
samples appears to be preserved and is essentially not modiﬁed by the
treatments administered.
Activating mutations in TCR signaling–related genes correlate
with molecular signatures reflecting higher T-cell activation and
with response to therapy
Sixty-six of 85 patients harboredmutations in TCR signaling genes. To
assess the biological and clinical impact of the tumor mutational status,
we focused on patients with mutations in TCR signaling–related genes
other than RHOA, designated hereafter as “TCR_Mut” (42/85 cases,
49%), and compared themwith thosewith onlyRHOA or no detectable
mutation, designated “TCR_WT” (43/85 cases, 51%) (Figure 6).
Mutations in TCR-related genes other than RHOA were virtually
nonoverlapping, and the vast majority (47/56 distinct variants, 84%)
were either functionally validated (n5 24) or predicted (n5 23) to be
biologically gain-of-functionmutants (Figure 6). Consequently, nearly
all TCR_Mut patients (39/42 patients, 93%) harbored at least 1
activating mutation.
There were no signiﬁcantly differentially expressed genes between
TCR_Mut and TCR_WT samples (supplemental Figure 4). However,
themolecular signatures of TCR_Mutwere signiﬁcantly enriched in 15
gene sets comparedwith TCR_WTby enrichment analysis (Figure 7A;
supplemental Table 7; supplemental Figure 5), reﬂecting the activation
of signaling pathways like PI3K, NF-kB,17 IRF4, and JAK-STAT, as
well as the upregulation of calcium-signaling target genes. This points
toward TCR signaling activation in TCR_Mut PTCLs. TCR_Mut
samples also showed enrichment in cell-cycle signatures reﬂecting
increased proliferative activity. Finally, there was a trend for TCR_Mut
samples to have downregulated proximalTCRsignalinggenes (signature
“T_cell”) such as TCR (TCRa, TCRb; CD3d, CD3g), signaling
molecules (LAT, TRIM, SAP, FYB, ZAP70), and cell surface markers
(adjustedP5 .10), a feature consistentwith sustained T-cell activation.51
Then, when comparing the clinical features and outcome of
TCR_Mut and TCR_WT patients, no signiﬁcant differences in
main clinical characteristics at presentation (supplemental Table 9) or in
OS(18vs40monthsmedianOS;5-yearOS20%vs29%;P5 .37)were
found (supplemental Figure 6). Strikingly, however, among the 59
patients (49AITL and 10TFH-like PTCLs)who received anthracyclin-
based induction chemotherapy, 11 of 33 (33%) TCR_Mut patients vs 2
of 26 (8%) TCR_WT (P 5 .02, supplemental Table 9) showed early
progression, relapse, or no response to treatment within the ﬁrst 6
months after diagnosis. This, however, did not translate into a
statistically signiﬁcant difference in PFS at 5 years (21% vs 24% for
TCR_Mut vs TCR_WT patients; P5 .15) (Figure 7B-C).
Discussion
In this study, we conﬁrmed the high prevalence of RHOAmutations in
TFH-derived PTCL, with most samples bearing the dominant-negative
G17V variant. Interestingly, we identiﬁed a newK18N variant in 3% of
the patients that presented activating features in in vitro assays. This
intriguingﬁnding of distinctRHOAmutations, with apparently opposite
functional properties in the same disease, was also recently documented
in ATLL.36,52 Further studies are warranted to understand how these
variants may contribute to the pathogenesis of PTCLs.
Apart fromRHOA alterations,we identiﬁedactivating andvirtually
mutually exclusive mutations in diverse TCR signaling genes in half
of TFH-derived lymphomas. Individually, the frequencies of these
mutations were variable, with the 5 most mutated genes (PLCG1,
CD28, PIK3 elements,GTF2I, CTNNB1) being altered in 14% to 5%
of the patients. CD28 and FYN mutations in AITL were previously
described in a small number of cases.12-14 Our study signiﬁcantly
expands these previous results and strongly supports a role of activated
TCR signaling in the pathogenesis of TFH-derived PTCLs, drawing
strong parallels with the role of BCR signaling in B-cell lymphomas.
Mutations in genes related to TCR costimulation and signaling were
recently reported in other PTCL entities, like cutaneous T-cell lympho-
mas, PTCL-NOS, and ATLL.20-24,53 Nonetheless, mutations in speciﬁc
genes are variably recurrent in distinct entites,24,25 and for a given gene,
the distribution of the mutations and their relative prevalence are
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Figure 5. Mapping and functional analysis of PLCG1 variants and CARD11 variants. (A) Schematic representation of PLCG1 protein with mapping of the 10
missense mutations identified in AITL (circles) or TFH-like PTCL (squares) cases. Previously described activating mutations are in green boldface and mutations
previously described but not functionally tested are underlined. (B) Monitoring of PLCG1-mediated MALT1 activation via a FRET-based reporter assay. Data are
represented as mean 6 SEM from 3 independent experiments. Significant differences in activation activity were determined using 1-way ANOVA (**P # .01; ***P #
.001). Representative western blot from a MALT1 activation experiment. PLCG1 expression is revealed by anti-Myc tag blotting, whereas MALT1 expression is shown
by anti-MALT1 antibody. (C) NFAT luciferase reporter assay monitoring activity of PLCG1 mutants, compared with previously reported activating mutants (green).
Data are represented as mean 6 SEM from 7 independent experiments. Significant differences in activation activity were determined using 1-way ANOVA (*P # .05;
**P # .01). Representative western blot from a luciferase assay experiment. Ectopic myc-tagged PLCG1 expression is revealed by anti-Myc. Anti-Actin blotting serves
as loading control. (D) Schematic representation of CARD11 protein with mapping of the 3-point mutations found in 2 AITL (circles) and 1 TFH-like PTCL-NOS
(square) patients. A previously described mutation is underlined. (E) Monitoring of CARD11-mediated MALT1 activation via a FRET-based reporter assay. Data are
1498 VALLOIS et al BLOOD, 15 SEPTEMBER 2016 x VOLUME 128, NUMBER 11
For personal use only. on January 31, 2017. by Yves Beguin www.bloodjournal.orgFrom 
heterogeneous. For instance, PLCG1 and CARD11 mutations are
highly prevalent (up to 18% and 15% of the cases, respectively) in
cutaneous T-cell lymphoma, in which conversely CD28mutations
are not found.20 CARD11 mutations are more frequent in ATLL
(24%) and Se´zary syndrome (10.9%) than in this series of TFH-
derived lymphomas. Whether the observed mutations are sufﬁcient
to induce constitutive activation of the respective pathways, and
how their effect may be dependent or inﬂuenced by antigen-driven
or other stimulatory signals remains unknown. Interestingly, some
of the TCR-related genes may be altered through point mutations
or small indels as well as by major structural rearrangements,
ampliﬁcations, and deletions.20,23,24 Collectively, these ﬁndings
strongly suggest that genetic alterations affecting TCR signaling
operate as a common pathogenic mechanism in several PTCL
entities.
Our analysis also explored the JAK/STAT and TLR pathways.
Mutation-induced activation of the JAK/STAT pathway, highly
prevalent in myeloid neoplasms, was recently identiﬁed as a major
oncogenic mechanism in several T-cell leukemias and lymphomas
derived from innate immune cells.20,37-43,53 Our results suggest,
however, that JAK/STAT mutations do not have the same importance
in the pathogenesis of TFH-derived lymphomas, because only 4 of 85
patients bore a single activatingmutation each in JAK1, JAK2, JAK3, or
MYD88 (Table 1).44 Except for JAK2 V617F, the 3 others were
observed in PLCG1-mutated cases.
Our data further support that AITL and TFH-like PTCL are
closely related at the molecular level5 and share common oncogenic
mechanisms. We and others have reported the occurrence of
TET2, DNMT3A, and RHOA mutations in a large proportion of
both AITL and TFH-like PTCL patients.5,8,9,12-14 This study
extends the molecular overlap across TFH-derived neoplasms to
genetic alterations in various TCR-signaling. Interestingly, CD28
mutations were exclusively identiﬁed in AITL patients, consistent
with recent reports.25,30 Similarly, IDH2 mutations were rarely
detected in PTCL cases,9,54 suggesting that the distribution of some
genetic features might be relevant in distinguishing AITL from other
TFH-derived nodal lymphomas, which otherwise share many
common features.5
In the proposed multistep model of pathogenesis for TFH-derived
PTCL, mutation-induced epigenetic deregulation, possibly arising
in early hematopoietic precursors, may promote the emergence of
premalignant cells, which requires additional genetic events to acquire a
deﬁnitively malignant phenotype.13,55 It has been thus suggested that
RHOA alterations occur as a second event in TET2- and/or DNMT3A-
mutated cells.13,55,56 The prevalence ofmutations inTET2,DNMT3A, and
IDH2 analyzed in a subset of our cases was 52% (34/65 cases), 29% (17/
56 cases), and 30% (21/71 cases), respectively.8,9 These mutations were
not mutually exclusive, and in fact tended to co-occur with each other, as
previously reported.12,13 We also found a tendency for RHOAmutations
to associate with epigenetic alterations, because RHOA mutations were
detected in 31 of 41 (76%) cases mutated in TET2, DNMT3A, and/or
IDH2, but in only 8 of 23 (35%) cases without epigenetic mutations
(P5 .003).Because theproportionof neoplastic cells inAITL is typically
low and variable from case to case,3 the comparison of VF of different
TCR mut, RHOA mut or wt
(n = 42/85)
TCR_Mut (49%) TCR_WT (51%)
RHOA
AITL TFH-like PTCL



















TCR wt, RHOA mut
(n = 24/85)
TCR wt, RHOA wt
(n = 19/85)
Figure 6. Mutual exclusivity of TCR signaling variants. The mutational status of TCR-related genes is represented for the 85 patients of the extended cohort. Genes
other than RHOA are ranked by decreasing mutation frequency and show an essentially mutually exclusive mutation pattern. In total, 49% of cases were mutated in
1 or several TCR-related gene(s) other than RHOA (hereafter considered as TCR_Mut), 28.5% were mutated in RHOA only, and 22.5% harbored no mutation in any
of the genes tested (collectively considered as TCR_WT).
Figure 5 (continued) represented as mean 6 SEM from 6 independent experiments. Significant differences in activation activity were determined using 1-way
ANOVA (*P # .05; **P # .01). The known activating L244P variant (green) was used as a positive control for the experiment. Representative western blot from a
MALT1 activation experiment. CARD11 expression is revealed by anti-HA tag blotting, whereas MALT1 expression is shown by anti-MALT1 antibody. (F) NF-kB
luciferase reporter assay in Jurkat cells deficient for CARD11 monitoring activity of CARD11 mutants, compared with previously reported activating mutants (green).
Data are represented as mean 6 SEM from 4 independent experiments. Significant differences in activation activity were determined using 2-way ANOVA (*P # .05;
**P # .01; ***P # .001 compared with WT PMA/IONO).
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mutated genes was performed for each individual sample. In 13 cases
harboring mutations in both TET2 and/or DNMT3, and RHOA or IDH2
with available VF, the TET2/DNMT3AVFwas signiﬁcantly higher than
for RHOA or IDH2 (supplemental Figure 7A). There was no obvious
association of RHOA mutations with other TCR-related genes, because
27of51 (53%)RHOA-mutatedand15of34 (44%)RHOA-WTcaseswere
mutated in other TCR-related genes (P5 .51). In 27 casesmutated in both
RHOA and one or several genes of the TCR, JAK/STAT, or TLR
pathways, no signiﬁcant difference in VF means was observed between
RHOA and other genes (supplemental Figure 7B).
Although our results warrant conﬁrmation in cohorts of patients
treated on prospective clinical trials, they suggest that the muta-
tional status of TCR-related genes may have important clinical
implications, predicting early treatment failure with anthracyclin-
based chemotherapy in TFH-related PTCL patients. Importantly,
several activating mutations found in PI3K or NF-kB pathways could
be targeted by idelalisib or the proteasome inhibitor bortezomib,
respectively. It is of interest to determine their efﬁcacy in TCR_Mut
patients,12,21 possibly in combination with demethylating agents.57
Thus, similar to the importance of targeting BCR signaling in B-cell
lymphomas with the BTK inhibitor ibrutinib,17 characterization of
the TCR mutational status might open new avenues to design
speciﬁc and more effective therapies. In clinical practice, given the
high number of genes involved and the diversity of mutations
found, targeted deep sequencing with high depth/coverage appears
to be the method of choice for selecting patients.
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